Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Sho Tazuma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3419-8444; OpenAlex author ID A5108719747. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers

Papers 9

  1. Minichromosome maintenance 4 is associated with poor survival and stemness of patients with pancreatic cancer. Co-author DOI 10.1007/s00795-025-00438-y↗
  2. Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors. Co-author DOI 10.1007/s12328-026-02388-z↗
  3. Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20710-4↗
  4. Real-world effectiveness of anamorelin in patients with unresectable and relapse pancreatic cancer: a prospective observational study. Co-author DOI 10.21037/jgo-2025-162↗
  5. Effects of transmembrane serine protease 4 on the survival in patients with pancreatic ductal adenocarcinoma undergoing surgery followed by adjuvant chemothera… Co-author DOI 10.1007/s00595-024-02824-y↗
  6. IQ Motif Containing GTPase-Activating Protein 3 Is Associated with Cancer Stemness and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000535542↗
  7. Effect of body fat mass loss on prognosis of radical resection for pancreatic ductal adenocarcinoma based on bioelectrical impedance analysis. Co-author DOI 10.1186/s12893-024-02315-4↗
  8. Expression of kinesin family member C1 in pancreatic ductal adenocarcinoma affects tumor progression and stemness. Co-author DOI 10.1016/j.prp.2022.154277↗
  9. Clinical features and images of malignant lymphoma localized in the pancreatic head to differentiate from pancreatic ductal adenocarcinoma: a case series study. Co-author DOI 10.1186/s12876-023-02779-3↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takeshi Sudo · 8 shared papers, 2023–2026 · strength 1.67
  2. Akira Ishikawa · 4 shared papers, 2023–2026 · strength 0.84
  3. Kenichiro Uemura · 3 shared papers, 2024–2026 · strength 0.76
  4. Shiro Oka · 3 shared papers, 2023–2026 · strength 0.70
  5. Hirotaka Tashiro · 3 shared papers, 2024–2026 · strength 0.69
  6. Yoshiyuki Shibata · 3 shared papers, 2024–2025 · strength 0.60
  7. Tatsuaki Sumiyoshi · 2 shared papers, 2026 · strength 0.55
  8. Atsushi Yamaguchi · 3 shared papers, 2023–2024 · strength 0.55
  9. Yasutaka Ishii · 2 shared papers, 2026 · strength 0.53
  10. Wataru Yasui · 2 shared papers, 2024–2026 · strength 0.47
  11. Shin’ya Takahashi · 2 shared papers, 2024 · strength 0.40
  12. Aya Kido · 2 shared papers, 2023–2024 · strength 0.36
  13. Naohide Oue · 2 shared papers, 2023–2024 · strength 0.36
  14. Naohiro Kato · 2 shared papers, 2023–2025 · strength 0.35
  15. Yosuke Shimizu · 1 shared paper, 2026 · strength 0.29
  16. Shinya Takahashi · 1 shared paper, 2026 · strength 0.29
  17. Kenta Baba · 1 shared paper, 2026 · strength 0.29
  18. Shinji Mii · 1 shared paper, 2026 · strength 0.27
  19. Yuto Fujiki · 1 shared paper, 2026 · strength 0.27
  20. Takumi Harada · 1 shared paper, 2026 · strength 0.26
  21. Shinya Takahashi · 1 shared paper, 2026 · strength 0.26
  22. Yoshiaki Murakami · 1 shared paper, 2026 · strength 0.26
  23. Kenjiro Okada · 1 shared paper, 2026 · strength 0.26
  24. Ryuta Shintakuya · 1 shared paper, 2026 · strength 0.26
  25. Juri Ikemoto · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.